Roche to acquire Poseida Therapeutics for $1.5bn

Roche has signed an agreement for the acquisition of Poseida Therapeutics in a deal representing a total value of up to $1.5bn.

Nov 27, 2024 - 06:00

Roche to acquire Poseida Therapeutics for $1.5bn

Roche has signed an agreement for the acquisition of Poseida Therapeutics in a deal representing a total value of up to $1.5bn.

Read the original article

Tags:

Previous Article

Gilead adds investigational HIV vaccine to its portfolio from Spanish biotech

Shorla Oncology’s IMKELDI approved by FDA for leukaemia cancers

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Opinion: Long Covid is a new name for an old syndrome

Opinion: Long Covid is a new name for an old syndrome

Sep 14, 2023

STAT+: Fiery MedPAC meeting highlights massive overpayments in Medicare Advantage

STAT+: Fiery MedPAC meeting highlights massive overpaym...

Jan 12, 2024

Which drugs are most likely to be approved in Non-infec...

Mar 28, 2024